CV Therapeutics (CVT) has high hopes for its angina drug Ranexa® (ranolazine extended release) after signing over the drug’s commercialisation rights to the Menarini Group in exchange for an upfront fee, milestones and royalties. However, CVT still retains the drug’s rights within the lucrative US and Japanese markets.